Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa
International Journal of Cancer, Volume 131, No. 4, Year 2012
Notification
URL copied to clipboard!
Description
Data on the prevalence of human papillomavirus (HPV) types in cervical carcinoma in women with HIV are scarce but are essential to elucidate the influence of immunity on the carcinogenicity of different HPV types, and the potential impact of prophylactic HPV vaccines in populations with high HIV prevalence. We conducted a multicentre case-case study in Kenya and South Africa. During 2007-2009, frozen tissue biopsies from women with cervical carcinoma were tested for HPV DNA using GP5+/6+-PCR assay. One hundred and six HIV-positive (mean age 40.8 years) and 129 HIV-negative women (mean age 45.7) with squamous cell carcinoma were included. Among HIV-positive women, the mean CD4 count was 334 cells/μL and 48.1% were on combined antiretroviral therapy. HIV-positive women had many more multiple HPV infections (21.6% of HPV-positive carcinomas) compared with HIV-negative women (3.3%) (p < 0.001) and the proportion of multiple infections was inversely related to CD4 level. An excess of HPV18 of borderline statistical significance was found in HIV-positive compared with HIV-negative cases (Prevalence ratio (PR) = 1.9, 95% confidence interval (CI): 1.0-3.7, adjusted for study centre, age and multiplicity of infection). HPV16 and/or 18 prevalence combined, however, was similar in HIV-positive (66.7%) and HIV-negative cases (69.1%) (PR = 1.0, 95% CI: 0.9-1.2). No significant difference was found for other HPV types. Our data suggest that current prophylactic HPV vaccines against HPV16 and 18 may prevent similar proportions of cervical SCC in HIV-positive as in HIV-negative women provided that vaccine-related protection is sustained after HIV infection. Copyright © 2011 UICC.
Authors & Co-Authors
de Vuyst, Hugo
France, Lyon
Centre International de Recherche Sur le Cancer
Ndirangu, Gathari
Kenya, Nairobi
Kenyatta National Hospital
Moodley, Manivasan
South Africa, Durban
University of Kwazulu-natal
Tenet, Vanessa
France, Lyon
Centre International de Recherche Sur le Cancer
Estambale, Benson B.A.
Kenya, Nairobi
University of Nairobi
Meijer, Chris J.L.M.
Netherlands, Amsterdam
Amsterdam Umc - Vrije Universiteit Amsterdam
Snijders, Peter Jf
Netherlands, Amsterdam
Amsterdam Umc - Vrije Universiteit Amsterdam
Clifford, Gary M.
France, Lyon
Centre International de Recherche Sur le Cancer
Franceschi, Silvia F.
France, Lyon
Centre International de Recherche Sur le Cancer
Statistics
Citations: 69
Authors: 9
Affiliations: 5
Identifiers
Doi:
10.1002/ijc.26470
ISSN:
00207136
e-ISSN:
10970215
Research Areas
Cancer
Genetics And Genomics
Infectious Diseases
Study Design
Cross Sectional Study
Case Study
Study Approach
Qualitative
Study Locations
Kenya
South Africa
Participants Gender
Female